The Cofepris (Federal Commission for the Protection of Sanitary Risks), authorized the registration of dabigatran etexilate to prevent the cerebral vascular event in patients with atrial fibrillation. In more than 50 years, there was not such a significant advance in terms of anticoagulants Worldwide.
Dabigatran etexilate is supported by the German laboratory Boehringer Ingelheim. Thanks to its own characteristics, it promises changes in the way in which patients will be treated atrial fibrillation , the type of cardiac arrtimia more common in adults, to prevent a cerebral vascular event or embolism.
This drug does not require continuous monitoring , has no interaction with food, or medication and offers a standard dose.
Until now, the regimens that are used to treat this type of patients, the so-called vitamin K antagonists, although effective, have limitations since they restrict the Lifestyle of the patient to take a special diet and, in addition, this must maintain a continuous monitoring of their levels of coagulation, through laboratory studies to ensure that you are not at risk of developing thrombi or clots potentially fatal.
Atrial fibrillation is a abnormality in the rhythm of the heart , in which, it beats faster or slower than normal; this irregularity can cause the formation of thrombi that eventually travel to the brain through the veins and arteries, and can lead the patient to suffer an embolism or cerebral vascular event .
It is estimated that in Mexico there could be 1 million people living with atrial fibrillation. Inevitably, 1 in 4 adults over 40 will develop this heart rhythm disorder.
The new drug is expected to be available in Mexico, during the next months. The approval of this type of medication allows thousands of patients to improve the way they live day to day with diseases like this one.
This information was published on the news portal grupoformula.com